Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Lipid storm within the lungs of severe COVID-19 patients: Extensive levels of cyclooxygenase and lipoxygenase-derived inflammatory metabolites

Anne-Sophie Archambault, Younes Zaid, Volatiana Rakotoarivelo, Étienne Doré, Isabelle Dubuc, Cyril Martin, Youssef Amar, Amine Cheikh, Hakima Fares, Amine El Hassani, Youssef Tijani, Michel Laviolette, Éric Boilard, Louis Flamand, Nicolas Flamand
doi: https://doi.org/10.1101/2020.12.04.20242115
Anne-Sophie Archambault
1Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Faculté de médecine, Département de médecine, Université Laval, Québec City, QC, Canada
2Canada Research Excellence Chair in the Microbiome-Endocannabinoidome Axis in Metabolic Health, Université Laval, Québec, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Younes Zaid
3Biology Department, Faculty of Sciences, Mohammed V University, Rabat, Morocco
4Cheikh Zaïd Hospital, Abulcasis University of Health Sciences, Rabat, Morocco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Volatiana Rakotoarivelo
1Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Faculté de médecine, Département de médecine, Université Laval, Québec City, QC, Canada
2Canada Research Excellence Chair in the Microbiome-Endocannabinoidome Axis in Metabolic Health, Université Laval, Québec, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Étienne Doré
5Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Canada
6Centre de Recherche Arthrite, Université Laval, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabelle Dubuc
5Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cyril Martin
1Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Faculté de médecine, Département de médecine, Université Laval, Québec City, QC, Canada
2Canada Research Excellence Chair in the Microbiome-Endocannabinoidome Axis in Metabolic Health, Université Laval, Québec, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Youssef Amar
7Moroccan Foundation for Advanced Science, Innovation & Research (MAScIR), Rabat, Morocco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amine Cheikh
4Cheikh Zaïd Hospital, Abulcasis University of Health Sciences, Rabat, Morocco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hakima Fares
4Cheikh Zaïd Hospital, Abulcasis University of Health Sciences, Rabat, Morocco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amine El Hassani
4Cheikh Zaïd Hospital, Abulcasis University of Health Sciences, Rabat, Morocco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Youssef Tijani
8Faculty of Medicine, Mohammed VI University of Health Sciences, Casablanca, Morocco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Laviolette
1Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Faculté de médecine, Département de médecine, Université Laval, Québec City, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Éric Boilard
5Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Canada
6Centre de Recherche Arthrite, Université Laval, Québec, Canada
9Département de microbiologie-infectiologie et d’immunologie, Université Laval, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis Flamand
5Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Canada
9Département de microbiologie-infectiologie et d’immunologie, Université Laval, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Nicolas.Flamand{at}criucpq.ulaval.ca Louis.Flamand{at}crchudequebec.ulaval.ca
Nicolas Flamand
1Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Faculté de médecine, Département de médecine, Université Laval, Québec City, QC, Canada
2Canada Research Excellence Chair in the Microbiome-Endocannabinoidome Axis in Metabolic Health, Université Laval, Québec, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Nicolas.Flamand{at}criucpq.ulaval.ca Louis.Flamand{at}crchudequebec.ulaval.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

BACKGROUND Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent responsible for Coronavirus disease 2019 (COVID-19). While SARS-CoV-2 infections are often benign, there are also severe COVID-19 cases, characterized by severe bilobar pneumonia that can decompensate to an acute respiratory distress syndrome, notably characterized by increased inflammation and a cytokine storm. While there is no cure against severe COVID-19 cases, some treatments significantly decrease the severity of the disease, notably aspirin and dexamethasone, which both directly or indirectly target the biosynthesis (and effects) of numerous bioactive lipids.

OBJECTIVE Our working hypothesis was that severe COVID-19 cases necessitating mechanical ventilation were characterized by increased bioactive lipid levels modulating lung inflammation. We thus quantitated several lung bioactive lipids using liquid chromatography combined to tandem mass spectrometry.

RESULTS We performed an exhaustive assessment of the lipid content of bronchoalveolar lavages from 25 healthy controls and 33 COVID-19 patients necessitating mechanical ventilation. Severe COVID-19 patients were characterized by increased fatty acid levels as well as an accompanying inflammatory lipid storm. As such, most quantified bioactive lipids were heavily increased. There was a predominance of cyclooxygenase metabolites, notably TXB2 >> PGE2 ∼ 12-HHTrE > PGD2. Leukotrienes were also increased, notably LTB4, 20-COOH-LTB4, LTE4, and eoxin E4. 15-lipoxygenase metabolites derived from linoleic, arachidonic, eicosapentaenoic and docosahexaenoic acids were also increased. Finally, yet importantly, specialized pro-resolving mediators, notably lipoxin A4 and the D-series resolvins, were also found at important levels, underscoring that the lipid storm occurring in severe SARS-CoV-2 infections involves pro- and anti-inflammatory lipids.

CONCLUSIONS Our data unmask the important lipid storm occurring in the lungs of patients afflicted with severe COVID-19. We discuss which clinically available drugs could be helpful at modulating the lipidome we observed in the hope of minimizing the deleterious effects of pro-inflammatory lipids and enhancing the effects of anti-inflammatory and/or pro-resolving lipids.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the Cheikh Zaid Foundation awarded to YZ and grants from the Canadian New Frontier Research Fund (NFRN-2019-00004) awarded to LF (PI), EB (co-PI) and NF (co-PI) and the Natural Sciences and Engineering Research Council of Canada awarded to NF. ASA received a doctoral award from the Canadian Institutes of Health Research. EB is recipient of a doctoral award from the Fonds de Recherche du Quebec en Santé (FRQS).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Local Ethics Committee of Cheikh Zaid Hospital in Rabat Morocco, by the local Ethics Committee of Institut universitaire de cardiologie et de pneumologie de Quebec-UL and by the local Ethics Committee of CHU de Quebec-UL. The study complies with the Declaration of Helsinki and all subjects signed a consent form.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding: This work was supported by the Cheikh Zaid Foundation awarded to YZ and grants from the Canadian New Frontier Research Fund (NFRN-2019-00004) awarded to LF (PI), EB (co-PI) and NF (co-PI) and the Natural Sciences and Engineering Research Council of Canada awarded to NF. ASA received a doctoral award from the Canadian Institutes of Health Research. ED and EB are respectfully recipient of doctoral and senior awards from the Fonds de Recherche du Québec en Santé (FRQS).

  • Abbreviations 2-AG, 2-arachidonoyl-glycerol; AA, arachidonic acid; AEA, N-arachidonoyl-ethanolamine; ALT, alanine transaminase; AST, aspartate transaminase; BAL, bronchoalveolar lavage; COVID-19, coronavirus disease 2019; COX, cyclooxygenase; CRP, C-reactive protein; DGLA, dihomo-γ-linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; EX, eoxin; HETE, hydroxyeicosatetraenoic acid; ICU, intensive care unit; IL, interleukin; LA, linoleic acid; LDH, lactate dehydrogenase; LOX, lipoxygenase; LT, leukotriene; PG, prostaglandin; Rv, resolvin; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SPM, specialized proresolving mediator; TX, thromboxane.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 07, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Lipid storm within the lungs of severe COVID-19 patients: Extensive levels of cyclooxygenase and lipoxygenase-derived inflammatory metabolites
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Lipid storm within the lungs of severe COVID-19 patients: Extensive levels of cyclooxygenase and lipoxygenase-derived inflammatory metabolites
Anne-Sophie Archambault, Younes Zaid, Volatiana Rakotoarivelo, Étienne Doré, Isabelle Dubuc, Cyril Martin, Youssef Amar, Amine Cheikh, Hakima Fares, Amine El Hassani, Youssef Tijani, Michel Laviolette, Éric Boilard, Louis Flamand, Nicolas Flamand
medRxiv 2020.12.04.20242115; doi: https://doi.org/10.1101/2020.12.04.20242115
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Lipid storm within the lungs of severe COVID-19 patients: Extensive levels of cyclooxygenase and lipoxygenase-derived inflammatory metabolites
Anne-Sophie Archambault, Younes Zaid, Volatiana Rakotoarivelo, Étienne Doré, Isabelle Dubuc, Cyril Martin, Youssef Amar, Amine Cheikh, Hakima Fares, Amine El Hassani, Youssef Tijani, Michel Laviolette, Éric Boilard, Louis Flamand, Nicolas Flamand
medRxiv 2020.12.04.20242115; doi: https://doi.org/10.1101/2020.12.04.20242115

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (758)
  • Anesthesia (222)
  • Cardiovascular Medicine (3313)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13397)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5175)
  • Geriatric Medicine (482)
  • Health Economics (785)
  • Health Informatics (3283)
  • Health Policy (1145)
  • Health Systems and Quality Improvement (1198)
  • Hematology (432)
  • HIV/AIDS (1023)
  • Infectious Diseases (except HIV/AIDS) (14651)
  • Intensive Care and Critical Care Medicine (915)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (525)
  • Neurology (4950)
  • Nursing (262)
  • Nutrition (734)
  • Obstetrics and Gynecology (888)
  • Occupational and Environmental Health (797)
  • Oncology (2530)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1305)
  • Pharmacology and Therapeutics (552)
  • Primary Care Research (558)
  • Psychiatry and Clinical Psychology (4223)
  • Public and Global Health (7525)
  • Radiology and Imaging (1713)
  • Rehabilitation Medicine and Physical Therapy (1018)
  • Respiratory Medicine (981)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (72)
  • Transplantation (237)
  • Urology (206)